Igor Puzanov - Dissemin

Papers authored by Igor Puzanov

This paper is made freely available by the publisher.

2014 Igor Puzanov

, Muhammad W. Saif, Saif Mw, Laura Goff, Grace K. Dy, Dy Gk, Paolo Zucali, Julie A. Means-Powell, Means Powell Ja, Wen Wee Ma, Ma Ww, Wen Wee, Matteo Simonelli and 8 other authors

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

Download from link.springer.com

Igor Puzanov

, Colin R. Lindsay, Lindsay Cr, Evans Tr, Laura W. Goff, Jeffrey A. Sosman, Jill Gilbert, Jordan Berlin, Srinivasu Poondru, Ronit Simantov, Richard Gedrich, Andrew Stephens, Emily Chan, T. R. Jeffry Evans, T. R. Jeffry Evans

A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

Download from clincancerres.aacrjournals.org

This paper was not found in any repository, but could be made available legally by the author.

Antoni Ribas, Rene Gonzalez, Anna Pavlick, Omid Hamid, Thomas F. Gajewski, Gajewski Tf, Adil Daud, Lawrence Flaherty, Theodore Logan, Bartosz Chmielowski, Karl Lewis, Damien Kee, Peter Boasberg, Ming Yin, Iris Chan and 5 other authors

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

Upload

Igor Puzanov

, Grant McArthur, Rene Gonzalez, Anna Pavlick, Omid Hamid, Thomas F. Gajewski, Gajewski Tf, Ming Yin, Jill Fredrickson, Nicholas Choong, Antoni Ribas

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7)

Download from dx.doi.org

This paper is available in a repository.

Maha Hussain, Stephanie Daignault, Neeraj Agarwal, Petros D. Grivas, Grivas Pd, Arlene O. Siefker-Radtke, Siefker Radtke Ao, Arlene O. Siefker???radtke, Igor Puzanov

, Ulka N. Vaishampayan, MacVicar Gr, Gary R. MacVicar, Evan Y. Yu, Levine Eg, Ellis Glenn Levine and 17 other authors

A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma

Download from www.ncbi.nlm.nih.gov

Abramson Vg, Keedy Vl, Douglas Buckner Johnson, Johnson Db, Kimberly H. Dahlman, Dahlman Kh, Jared D. Knol, Kimberly Brown Dahlman, Jill Gilbert, Igor Puzanov

, Julie Ann Means-Powell, Balko Jm, Justin M. Balko, Lovly Cm, Christine Marie Lovly

and 20 other authors

Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel

Download from doi.org

Suzanne L. Topalian, Topalian Sl, Mario Sznol, David F. McDermott, McDermott Df, Harriet M. Kluger, Kluger Hm, Richard D. Carvajal, Carvajal Rd, William H. Sharfman, Sharfman Wh, Julie R. Brahmer, Brahmer Jr, Donald P. Lawrence, Lawrence Dp and 24 other authors

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Download from doi.org

Miller Wh, Shailender Bhatia, Brendan, Brendan Curti, Marc S. Ernstoff, Ernstoff Ms, Michael Gordon, Michael, Elisabeth I. Heath, Heath Ei, Wilson H. Miller, Igor Puzanov

, Thomas, David I. Quinn, Quinn Di and 16 other authors

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

Download from link.springer.com

Yibing Yan, Grant McArthur, Omid Hamid, Igor Puzanov

, Rene Gonzalez, Thomas Gajewski, Yulei Wang, Matthew Wongchenko, Nicholas Choong, Antoni Ribas

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma

Download from dx.doi.org

2013 Katherine E. Hutchinson, Hutchinson Ke, Doron Lipson, Stephens Pj, Philip J. Stephens, Geoff Otto, Lehmann Bd, Brian D. Lehmann, Cindy L. Vnencak-Jones, Pamela L. Lyle, Lyle Pl, Vnencak Jones Cl, Ross Js, Jeffrey S. Ross, Pietenpol Ja and 7 other authors

BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

Download from aacrjournals.org

Kerstin Trunzer, Anna C. Pavlick, Pavlick Ac, Lynn Schuchter, Rene Gonzalez, Grant A. McArthur, Thomas E. Hutson, McArthur Ga, Stergios J. Moschos, Jeffrey S. Weber

, Hutson Te, Moschos Sj, Keith T. Flaherty, Kevin B. Kim, Peter Hersey and 26 other authors

Pharmacodynamic effects and mechanisms of resistance to Vemurafenib in patients with metastatic melanoma

Download from doi.org

Uday B. Dandamudi, Dandamudi Ub, Urba Wj, Musie Ghebremichael, Sosman Ja, Jeffrey A. Sosman, Joseph I. Clark, Clark Ji, McDermott Df, David F. McDermott, Michael B. Atkins, Atkins Mb, Janice P. Dutcher, Dutcher Jp, Walter J. Urba and 15 other authors

A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: A Cytokine Working Group (CWG) Study

Upload

Igor Puzanov

, Mohammed Milhem, Robert Andtbacka, David Minor, Omid Hamid, Ai Li, Ari VanderWalde, Howard Kaufman

Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma

Download from dx.doi.org

2012 Jenny Wu, Ph Clingen, Vj Spanswick, Maria Mellinas-Gomez, Tim Meyer, Igor Puzanov

, Duncan Jodrell, Daniel Hochhauser, Ja Hartley

γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000).

Download from clincancerres.aacrjournals.org

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Long Gv, U. Trefzer, Davies Ma, Kefford Rf, Ascierto Pa, Chapman Pb, I. Puzanov

, A. Hauschild, C. Robert, A. Algazi, L. Mortier, H. Tawbi, T. Wilhelm, L. Zimmer, J. Switzky and 5 other authors

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

Upload

Keith T. Flaherty, Flaherty Kt, Jeffery R. Infante, Adil Daud, Infante Jr, Rene Gonzalez, Richard F. Kefford, Jeffrey Sosman, Kefford Rf, Omid Hamid, Lynn Schuchter, Jonathan Cebon, Nageatte Ibrahim, Ragini Kudchadkar, Howard A. Burris and 16 other authors

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Download from www.ncbi.nlm.nih.gov

A. Poprach, T. Pavlik, B. Melichar, I. Puzanov

, L. Dusek, Z. Bortlicek, R. Vyzula, J. Abrahamova, T. Buchler, Czech Renal Cancer Cooperative Group

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: A national registry-based study

Download from academic.oup.com

Daniel C. Cho, Cho Dc, Thomas E. Hutson, Hutson Te, Nicholas J. Vogelzang, Wolfram Samlowski, Peter Sportelli, Brad Somer, Paul Richards, Sosman Ja, Jeffrey A. Sosman, Igor Puzanov

, Michaelson Md, M. Dror Michaelson, Keith T. Flaherty and 4 other authors

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Download from www.ncbi.nlm.nih.gov

Kim Margolin, Marc S. Ernstoff, Ernstoff Ms, Omid Hamid, Donald Lawrence, Jedd D. Wolchok, David McDermott, Igor Puzanov

, Wolchok Jd, Joseph I. Clark, Clark Ji, Mario Sznol, Theodore F. Logan, Logan Tf, Jon Richards and 6 other authors

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

Upload

Samit Patrawala, Igor Puzanov

Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor

Download from doi.org

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

Papers authored by Igor Puzanov